- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion date, Trial termination, PD(L)-1 Biomarker, Metastases: Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer (clinicaltrials.gov) - May 1, 2019 P2, N=10, Terminated, Trial completion date: May 2020 --> Nov 2018 | Active, not recruiting --> Terminated; Study did not meet first stage requirements of interim analysis
- |||||||||| rolinsatamab talirine (ABBV-176) / AbbVie
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) (clinicaltrials.gov) - Nov 29, 2018 P1, N=19, Terminated, Trial completion date: May 2020 --> Nov 2018 | Active, not recruiting --> Terminated; Study did not meet first stage requirements of interim analysis N=120 --> 19 | Trial completion date: Mar 2020 --> Nov 2018 | Suspended --> Terminated | Trial primary completion date: Jun 2019 --> Nov 2018; Safety
- |||||||||| Enrollment change, Trial termination, Trial primary completion date, Metastases: Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer (clinicaltrials.gov) - Sep 29, 2017
P2, N=6, Terminated, Recruiting --> Completed | Trial primary completion date: Feb 2019 --> Nov 2016 N=40 --> 6 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Jul 2011; Slow enrollment
- |||||||||| veliparib (ABT-888) / AbbVie
Enrollment change, Trial withdrawal, Combination therapy, PARP Biomarker, Metastases: Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor (clinicaltrials.gov) - Sep 28, 2017 P1, N=0, Withdrawn, N=40 --> 6 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Jul 2011; Slow enrollment N=20 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| veliparib (ABT-888) / AbbVie
Trial initiation date, Trial primary completion date, Combination therapy, PARP Biomarker, Metastases: Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor (clinicaltrials.gov) - Jul 19, 2017 P1, N=20, Not yet recruiting, Not yet recruiting --> Recruiting Initiation date: Aug 2016 --> Dec 2017 | Trial primary completion date: Sep 2018 --> Feb 2019
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment closed, Enrollment change, PD(L)-1 Biomarker, Metastases: Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer (clinicaltrials.gov) - May 30, 2017 P2, N=10, Active, not recruiting, Initiation date: Aug 2016 --> Dec 2017 | Trial primary completion date: Sep 2018 --> Feb 2019 Recruiting --> Active, not recruiting | N=33 --> 10
- |||||||||| veliparib (ABT-888) / AbbVie
New P1 trial, Combination therapy, PARP Biomarker, Metastases: Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor (clinicaltrials.gov) - Jul 13, 2016 P1, N=20, Not yet recruiting,
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment open, PD(L)-1 Biomarker, Metastases: Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer (clinicaltrials.gov) - Apr 24, 2016 P2, N=33, Recruiting, Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Not yet recruiting --> Recruiting
- |||||||||| Enrollment change, Trial primary completion date, Metastases: Possible New Therapy for Advanced Cancer (clinicaltrials.gov) - Nov 19, 2014
P1/2, N=9, Terminated, Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Apr 2015 N=36 --> 9 | Trial primary completion date: Dec 2015 --> Mar 2014
- |||||||||| Trial termination, Metastases: Possible New Therapy for Advanced Cancer (clinicaltrials.gov) - Nov 18, 2014
P1/2, N=36, Terminated, N=36 --> 9 | Trial primary completion date: Dec 2015 --> Mar 2014 Recruiting --> Terminated; Business decision by the sponsor during Phase 1.
- |||||||||| nevanimibe (ATR-101) / Millendo Therap
Enrollment change, Trial primary completion date, Metastases: Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) - Aug 21, 2014 P1, N=59, Recruiting, Recruiting --> Terminated; Business decision by the sponsor during Phase 1. N=21 --> 59 | Trial primary completion date: Aug 2014 --> Jun 2015
- |||||||||| cixutumumab (IMC A12) / Eli Lilly, Lysodren (mitotane) / HRA Pharma
Trial termination, Surgery, Metastases: IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 29, 2013 P2, N=20, Terminated, N=42 --> 56 Active, not recruiting --> Terminated; The trial was permanently halted due to futility concerns.
- |||||||||| cixutumumab (IMC A12) / Eli Lilly, Lysodren (mitotane) / HRA Pharma
Enrollment change, Surgery, Metastases: IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 29, 2013 P2, N=20, Terminated, Active, not recruiting --> Terminated; The trial was permanently halted due to futility concerns. N=122 --> 20
|